The place of pegvisomant in the management of acromegaly

Bibliography

• ALEXANDER L, APPLETON D, HALLR, ROSS WM, WILKINSON R: Epidemiology of acromegaly in the Newcastle region. CM]. Eridocrinol. (1980) 12:71–79.
   Web of Science ®Google Scholar
• BENGTSSON BA, EDEN S, ERNEST I,ODEN A, SJOGREN B: Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Land. (1988) 223:327–335.
   Google Scholar
• MELMED S: Acromegaly. N Engl. I Med. (1990) 322:966–977.
   PubMed Web of Science ®Google Scholar
• NABARRO JD: Acromegaly. CM]. Eridocnnol (1987) 26 :481–521.
   Google Scholar
• OHLSSON C, LOVSTEDT K, HOLMES PV et al.: Embryonic stem cells express growth hormone receptors: regulation by retinoic acid. Endocrinology (1993) 133:2897–2903.
   PubMed Web of Science ®Google Scholar
• NYBERG F BURMAN P: Growth hormone and its receptors in the central nervous system--location and functional significance. Horm. Res. (1996) 45:18–22.
   PubMed Web of Science ®Google Scholar
• HILL DJ, RILEY SC, BASSETT NS, WATERS MJ: Localization of the growth hormone receptor, identified by immunocytochemistry, in second trimester human fetal tissues and in placenta throughout gestation. j Chic Eric/or/Ma Metab. (1992) 75:646–650.
   PubMed Web of Science ®Google Scholar
• BARKAN AL, BEITINS IZ, KELCH RP: Plasma insulin-like growth factor-I/ somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. j Chic Eridocnnol Metab. (1988) 67:69–73.
   PubMed Web of Science ®Google Scholar
• CLEMMONS DR, VAN WYK JJ, RIDGWAY EC etal.: Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl. j Med. (1979) 301:1138–1142.
   Google Scholar
• MATHEWS DR, HOSKER JP, RUDENSKI AS et al.: Homeostasis model assessment:insulin resistance and B cell-function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 28:412–419.
   PubMed Web of Science ®Google Scholar
• PARKINSON C, BESSER GM, TRAINER PJ, THE SENSUS ACROMEGALY STUDY GROUP: Demonstration of long-term improvement in subjective and objective assessments of well-being in patients with acromegaly treated with pegvisomant. 20th Joint meeting of the British Endocrine Societies, 26-29th March 2001, Belfast, UK. Endocrine Abstracts (2001) Vol 1. 0C23 (2001).
   Google Scholar
• PARKINSON C, FLYVBJERG A, YATES A, TRAINER PJ: Effect of pegvisomant-induced normalization of serum IGF-I on IGF-II, IGF binding proteins and insulin resistance in active acromegaly. 83rd Annual Meeting of the Endocrine Socien", Denver Colorado, USA. 20M-23rd June 2001. Poster 3-354(2001).
   Google Scholar
• •The first paper to convincingly demonstrate the need for tight control of serum GH in patients with acromegaly and increased mortality in patients with values above 5 mU/1.
   Google Scholar
• WRIGHT AD, HILL DM, LOWY C, FRASER TR: Mortality in acromegaly. WM (1970) 39:1–16.
   Web of Science ®Google Scholar
• BATES AS, VAN'T HOFF W, JONES JM,CLAYTON RN: An audit of outcome of treatment in acromegaly. WM (1993) 86:293–299.
   Web of Science ®Google Scholar
• RAJASOORYA C, HOLDAWAY IM, WRIGHTSON P, SCOTT DJ, IBBERTSON HK: Determinants of clinical outcome and survival in acromegaly. Chic Eridocnnol (1994) 41:95–102.
   Google Scholar
• MOLITCH ME: Clinical manifestations ofacromegaly. Eridocnnol Metab. Chic North Am. (1992) 21:597–614.
   PubMed Web of Science ®Google Scholar
• ORME SM, MCNALLY RJQ, CARTWRIGHT RA, BELCHETZ PE: Mortality and cancer incidence in acromegaly: A Retrospective Cohort Study. Chic Eridocrinol Metab. (1998) 83:2730–2734.
   PubMed Web of Science ®Google Scholar
• ABOSCH A, TYRELL B, LAMBORN K et al.: Transspenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Chic Eridocrinol Metab. (1998) 83:3411–3418.
   PubMed Web of Science ®Google Scholar
• •A representative study detailing the (lack of) effectiveness of pituitary surgery in many patients.
   Google Scholar
• SWEARINGEN B, BARKER FG, KATZNELSON L et al: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. j Chic Eridocnnol Metab. (1998) 83:3419–3426.
   PubMed Web of Science ®Google Scholar
• GIUSTINA A, BARKAN A, CASANUEVA FF et al: Criteria for cure of acromegaly: a consensus statement. j CM]. Eridocnnol Metab. (2000) 85:526–529.
   PubMed Web of Science ®Google Scholar
• SHEAVES R, JENKINS P, BLACKBURN P et al.: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Chic Eridocnnol (1996) 45:407–413.
   Google Scholar
• AHMED S, ELSHEIKH M, STRATTON IM et al: Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Chic Eridocrinol (1999) 50:561–567.
   Web of Science ®Google Scholar
• JENKINS S, O'BRIEN I, JOHNSON A et al.: The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. CM]. Eridocnnol (1995) 43:517–522.
   Google Scholar
• LISSETT CA, PEACY SR, LAING I et al:The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreating adenomas. Chic Eridocrinol (1998) 49:653–658.
   Web of Science ®Google Scholar
• GITTOES NJ, SHEPPARD MC, JOHNSON AP, STEWART PM: Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. WM(1999) 92:741–745.
   Google Scholar
• DOWSETT RJ, FOWBLE B, SERGOTT RC et al.: Results of radiotherapy in the treatment of acromegaly: lack of ophthalmologic complications. Intl. Radiat Oricol Biol. Phys. (1990) 19:453–459.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ, FOWBLE BF, SCHATZ NJ,SAVINO PJ, GENNARELLI TA: Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med. (1986) 81:457–462.
   PubMed Web of Science ®Google Scholar
• TRAMPE EA, LUNDELL G, LAX I, WERNER S: External irradiation of growth hormone producing pituitary adenomas: prolactin as a marker of hypothalamic and pituitary effects. Intl Radiat .Oricol. Biol. Phys. (1991) 20:655–660.
   PubMed Web of Science ®Google Scholar
• •A representative study detailing the effects of pituitary radiotherapy and the slow onset of action.
   Google Scholar
• EASTMAN RC, GORDEN P, ROTH J: Conventional supervoltage irradiation is an effective treatment for acromegaly. I Chic Eridocrinol Metab (1979) 48:931–940.
   PubMed Web of Science ®Google Scholar
• EASTMAN RC, GORDEN P, GLATSTEIN E, ROTH J: Radiation therapy of acromegaly. Eridocnnol Metab arc North Am. (1992) 21:693–712.
   PubMed Web of Science ®Google Scholar
• BIERMASZ NR, DULKEN HV, ROELFSEMA F: Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Gun. Eric/0mila (2000) 53:321–327.
   Google Scholar
• VERHEY LJ, SMITH V, SERAGO CF: Comparison of radiosurgery treatment modalities based on physical dose distributions. Int. j RadMt. Oncol Biol. Phys. (1998) 40:497–505.
   PubMed Web of Science ®Google Scholar
• LIM YL, LEEM W, KIM TS, RHEE BA, KIM GK: Four years' experiences in the treatment of pituitary adenomas with gamma knife radiosurgery. Stereotact. Funct. Neurosurg. (1998) 70\(Suppl. 1):95–109.
   Google Scholar
• JACKSON IM NOREN G: Role of gamma knife therapy in the management of pituitary tumors. Endocnbol. Metab. North Am. (1999) 28:133–142.
   PubMed Web of Science ®Google Scholar
• LANDOLT AM, HALLER D, LOMAX N et al.: Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. j Neurosurg. (1998) 88:1002–1008.
   PubMed Web of Science ®Google Scholar
• PLOWMAN PN: Pituitary adenoma radiotherapy - when, who and how? Clin. Endocrinol (1999) 51:265–271.
   Web of Science ®Google Scholar
• WASS JA, THORNER MO, MORRIS DV et al.: Long-term treatment of acromegaly with bromocriptine. Br Med. j (1977) 1:875–878.
   PubMed Web of Science ®Google Scholar
• JAFFE CA BARKAN AL: Treatment of actomegaly with dopamine agonists. Endocrinol Metab. Gun. North Am. (1992) 21:713–715.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the effectiveness of dopamine agonist therapy in acromegaly.
   Google Scholar
• CHIODINI PG, COZZI R, DALLABONZANA D et al: Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. j Clin. Endocrinol Metab. (1987) 64:447–453.
   PubMed Web of Science ®Google Scholar
• HALSE J, HARRIS AG, KVISTBORG A etal.: A randomized study of SMS 201–995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. j Gun. Endocnbol. Metab. (1990) 70:1254–1261.
   Google Scholar
• MOSES AC, MOLITCH ME, SAWIN CT et al.: Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C. j Clin. Endocnbol. Metab. (1981) 53:752–758.
   PubMed Web of Science ®Google Scholar
• WASS JA, CLEMMONS DR, UNDERWOOD LE etal.: Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Endocrinol (1982) 17:369–377.
   Google Scholar
• CHIODINI PG, ATTANASIO R, COZZI R et al: CV 205-502 in acromegaly. ActaEndocnbol (Coperil) (1993) 128:389–393.
   Google Scholar
• COLAO A, FERONE D, MARZULLO P et al.: Effect of different dopaminergic agents in the treatment of acromegaly. Endocrinol Metab .(1997) 82:518–523.
   Web of Science ®Google Scholar
• ABS R, VERHELST J, MATTER D etal.:Cabergoline in the treatment of acromegaly: a study in 64 patients. j Gun. Endocnbol. Metab. (1998) 83:374–378.
   Google Scholar
• FERRARI C, PARACCHI A, ROMANO C et al: Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol (1988) 29:467–476.
   PubMed Web of Science ®Google Scholar
• JACKSON SN, FOWLER J, HOWLETT TA: Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocnbol. (1997) 46:745–749.
   PubMed Web of Science ®Google Scholar
• MURATORI M, AROSIO M, GAMBINO G et al: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. j Endocrinol Invest. (1997) 20:537–546.
   PubMed Web of Science ®Google Scholar
• REUBI JC, KVOLS L, KRENNING E, LAMBERTS SW: Distribution of somatostatin receptors in normal and tumor tissue. Metabolism (1990) 39\(Suppl. 2):78–81.
   Google Scholar
• YAMADA Y, POST SR, WANG K et al: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Nati Acad. Sci. USA (1992) 89:251–255.
   PubMed Web of Science ®Google Scholar
• YAMADA Y, REISINE T, LAW SF etal.: Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mal Endocnbol. (1992) 6:2136–2142.
   Google Scholar
• BRUNO JF, XU Y, SONG J, BERELOWITZ M: Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc. Natl. Acad. Se USA (1992) 89:11151–11155.
   PubMed Web of Science ®Google Scholar
• O'CARROLL AM, LOLAIT SJ, KONIG M, MAHAN LC: Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol (1992) 42:939-946. Published erratum appears in Mal Pharmacol (1993) Dec 44(6):1278.
   Google Scholar
• BAUER W BRINER U, DOEPFNER W etal.: SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci (1982) 31:1133–1140.
   Google Scholar
• REICHLIN S: Somatostatin. N Engl. Med. (1983) 309:1495–1501; 1556–1563.
   Google Scholar
• PATEL YC SRIKANT CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology (1994) 135:2814–2817.
   PubMed Web of Science ®Google Scholar
• BRUNS C, WECKBECKER G, RAULF F eta].: Molecular pharmacology of somatostatin-receptor subtypes. Ann. NY Acad. Sci. (1994) 733:138–146.
   PubMed Web of Science ®Google Scholar
• EZZAT S, SNYDER PJ, YOUNG WF et al.: Octreotide treatment of acromegaly. A randomized, multicenter study. Ann. Intern. Med. (1992) 117:711–718.
   PubMed Web of Science ®Google Scholar
• EZZAT S, REDELMEIER DA, GNEHM M, HARRIS AG: A prospective multicenter octreotide dose response study in the treatment of acromegaly. j Endocrinol Invest. (1995) 18:364–369.
   PubMed Web of Science ®Google Scholar
• NEWMAN B, MELMED S, SNYDER PJ eta].: Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. j Glin. Endocrinol Metab. (1995) 80:2768–2775.
   Google Scholar
• LAMBERTS SW, VAN DER LELY AJ, DE HERDER WW, HOFLAND LJ: Octreotide. N Engl. j Med. (1996) 334:246–254.
   PubMed Web of Science ®Google Scholar
• •An excellent review of SMS analogues and octreotide.
   Google Scholar
• LAMBERTS SW, UITTERLINDEN P, SCHUIJFF PC, KLIJN JG: Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Glin. Endocrinol (1988) 29:411–420.
   PubMed Web of Science ®Google Scholar
• VANCE ML HARRIS AG: Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch. Int. Med. (1991) 151:1573–1578.
   Web of Science ®Google Scholar
• CHRISTENSEN SE, WEEKE J, ORSKOV H et al: Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin. Endocnbol. (1987) 29:297–306.
   Google Scholar
• LACRANJAN I ATKINSON AB: The Sandostatin LSR Group. Results of a European Multicentre study with Sandostatin LAR in acromegalic patients. Pituitary (1999) 1:105–114.
   Google Scholar
• AL-MASKARI M, GEBBIE J, KENDALL-TAYLOR P: The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin. Endocrinol. (1996) 45:415–421.
   PubMed Web of Science ®Google Scholar
• GIUSTI M, GUSSONI G, CUTTICA CM, GIORDANO G: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. j OM. Endocrinol. Metab. (1996) 81:2089–2097.
   PubMed Web of Science ®Google Scholar
• SULIMAN M, JENKINS R, ROSS R et al.: Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. Endocrinol. Invest. (1999) 22:409–418.
   PubMed Web of Science ®Google Scholar
• REDFERN JS FORTUNER WJ 2ND: Octreotide-associated binary tract dysfunction and gallstone formation: pathophysiology and management. Am. Castroenterol. (1995) 90:1042–1052.
   PubMed Web of Science ®Google Scholar
• DOWLING RH, HUSSAINI SH, MURPHY GM, BESSER GM, WASS JA: Gallstones during octreotide therapy. Metabolism (1992) 41 (Suppl. 2):22–33.
   Google Scholar
• HIRT H, KIMELMAN J, BIRNBAUM MJ et al.: The human growth hormone gene locus: structure, evolution, and allelic variations. DNA (1987) 6:59–70.
   PubMedGoogle Scholar
• ANDREWS P: Molecular weight of human placental lactogen investigated by gel filtration. Biochem. J. (1969) 111:799–800.
   PubMed Web of Science ®Google Scholar
• DELLACHA JM, ENERO MA, FAIFERMAN I: Molecular weight of bovine growth hormone. ExperientM (1966) 22:16–17.
   PubMedGoogle Scholar
• MILLER WL, MARTIAL JA, BAXTER JD: Molecular cloning of DNA complementary to bovine growth hormone mRNA. j Biol. Chem. (1980) 255:7521–7524.
   PubMed Web of Science ®Google Scholar
• DE VOS AM, ULTSCH M, KOSSIAKOFF AA: Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science (1992) 255:306–312.
   PubMed Web of Science ®Google Scholar
• ••The critical paper detailing the GH(GHR x 2) complex in normal GH binding.
   Google Scholar
• ABDEL-MEGUID SS, SHIEH HS, SMITH WW et al.: Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc. Natl. Acad. Sci. USA (1987) 84:6434–6437.
   PubMed Web of Science ®Google Scholar
• KELLY PA, DJIANE J, POSTEL-VINAY MC, EDERY M: The prolactinigrowth hormone receptor family. Endocr. Rev (1991) 12:235–251.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM BC, JHURANI P, WELLS JA: Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science (1989) 243:1330–1336.
   PubMed Web of Science ®Google Scholar
• CHEN WY, WIGHT DC, MEHTA BV, WAGNER TE, KOP CHICK JJ: Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Ma. Endocrinol. (1991) 5:1845–1852.
   PubMed Web of Science ®Google Scholar
• ••The first report of a GH receptorantagonist and its in vivo effects.
   Google Scholar
• OKADA S, CHEN WY, WIEHL P et al.: A growth hormone (GH) analog can antagonize the ability of native GH to promote differentiation of 3T3-F442A preadipocytes and stimulate insulin-like and lipolytic activities in primary rat adipocytes. Endocrinology (1992) 130:2284–2290.
   PubMed Web of Science ®Google Scholar
• ZALIPSKY S LEE C: Use of functionalized polyethylene glycols for modification of polypeptides. In: PEG Chemistry: Biotechnical and Biomedical Applications. Harris JM,Plenum Publishing Corp,New York, USA. (1992):347–370.
   Google Scholar
• FRANCIS GE, DELGADO C, GISHER D: Peg-modified proteins. In: Stability of protein pharmaceuticals, Part B: In vivo pathways of degradation and strategies for protein stabilization. Ahern TJ, Manning MC (Eds.), Plenum Press, New York USA. (1992):235–285.
   Google Scholar
• FUH G, CUNNINGHAM BC, FUKUNAGA R et al.: Rational design of potent antagonists to the human growth hormone receptor. Science (1992) 256:1677–1680.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM BC WELLS JA: Rational design of receptor-specific variants of human growth hormone. Proc. Nati Acad. Sci. USA (1991) 88:3407–3411.
   PubMed Web of Science ®Google Scholar
• TRAINER PJ, DRAKE WM, KATZNELSON L et al.: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Eng] J. Med. (2000) 342:1171–1177.
   PubMed Web of Science ®Google Scholar
• ••A significant clinical study detailing theeffectiveness of pegvisomant in patients with acromegaly.
   Google Scholar
• WILSON ME: Effects of estradiol and exogenous insulin-like growth Factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism. Endocrinol. Metab. (1998) 83:4013–4021.
   Web of Science ®Google Scholar
• THORNER MO, STRASBURGER CJ, WU Z etal.: Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. j Clin. Endocrinol. Metab. (1999) 84:2098–2103.
   Google Scholar
• VAN DER LELY AJ, LAMBERTS SWJ, BARKAN A et al.: A six week, double blind, placebo controlled study of a growth hormone antagonist, B2036-PEG (Trovert) in acromegalic patients. The Endocrine Socieg, 80th Annual Meeting (1998) June 24–27:New Orleans, Louisiana-OR 4–1, USA.
   Google Scholar
• GREENMAN Y MELMED S: Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. j Clin. Endocrinol. Metab. (1994) 78:398–403.
   PubMed Web of Science ®Google Scholar
• HERMAN-BONERT VS, ZIB K, SCARLETT JA, MELMED S: Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. I Clin. Endocrinol. Metab. (2000) 85:2958–2961.
   PubMed Web of Science ®Google Scholar
• •The first paper to document the effectiveness of pegvisomant in somatostatin resistant patients.
   Google Scholar
• MELMED S: Confusion in clinical and laboratory GH and IGF-I reports. Pituitary (1999) 2:171–172.
   PubMedGoogle Scholar
• TOOGOOD AA, JONES J, O'NEILL PA, THORNER MO, SHALET SM: The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. OM. Eric/or/Ma (1998) 48:569–576.
   Google Scholar
• GIUSTINA A VELDHUIS JD: Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev (1998) 19:717–797.
   PubMed Web of Science ®Google Scholar
• ASA SL, COSCHIGANO KT, BELLUSH L, KOPCHICK JJ, EZZAT S: Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. Am. J. Pathol. (2000) 156:1009–1015.
   PubMed Web of Science ®Google Scholar
• VELDHUIS JD, BIDLINGMAIER M, WU Z, STRASBURGER CJ: A selective recombinant human (li) GH-receptor antagonist fails to impede metabolic removal of endogenous or exogenous GH in healthy adults: evidence that the GH receptor does not participate primarily in the in vivo GH elimination process. 11th International Congress of Endocrinology (2000) Sydney, Australia. P405.
   Google Scholar
• HUTSON RK: MRI morphologic analysis of GH-secreting tumor response to growth hormone receptor antagonist therapy. 1 1 th International Congress of Endocrinology (2000) Sydney, Australia. P462.
   Google Scholar
• VAN DER LELY AJ, MULLER A, JANSSEN JA etal.: Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. arr. Endocrinol Metab. (2001) 2:478–481.
   Google Scholar
• •The first paper to document combined use of somatostatin analogues and pegvisomant to control tumour growth.
   Google Scholar
• KLEIN R, KLEIN BE, MOSS SE: The Wisconsin epidemiological study of diabetic retinopathy: a review. Diab. Metab. Rev (1989) 5:559–570.
   PubMed Web of Science ®Google Scholar
• POULSEN JE: The Houssay phenomenonin man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes (1953) 2:7–12.
   PubMed Web of Science ®Google Scholar
• JOPLIN GF, OAKLEY NW, HILL DW, KOHNER EM, FRASER TR: Diabetic retinopathy. II. Comparison of disease remission induced by various degrees of pituitary ablation by Y90. Diabetaogia (1967) 3(4): 406–412.
   Google Scholar
• SHARP PS, FALLON TJ, BRAZIER OJ et al.: Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetaugia (1987) 30:199–207.
   PubMed Web of Science ®Google Scholar
• GRANT M, RUSSELL B, FITZGERALD C, MERIMEE TJ: Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes (1986) 35:416–420.
   PubMed Web of Science ®Google Scholar
• MEYER-SCHWICKERATH R, PFEIFFER A, BLUM WF etal.: Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. (1993) 92:2620–2625.
   Google Scholar
• GRANT MB, MAMES RN, FITZGERALD C et al.: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care (2000) 23:504–509.
   PubMed Web of Science ®Google Scholar
• GEHRS KM: Efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care (2001) 24:182–183.
   PubMedGoogle Scholar
• SMITH LE, KOPCHICK JJ, CHEN Wet al.: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science (1997) 276:1706–1709.
   Google Scholar
• BLANKESTIJN PJ, DERKX FH, BIRKENHAGER JC et al.: Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion. J. arr. Endocrinol Metab. (1993) 77:498–502.
   PubMed Web of Science ®Google Scholar
• ASSAD SN, EL-LAKANY S, ABDEL KADER M: Functional and structural changes of the kidney in acromegaly. The Endocrine Society's 82nd Annual Meeting, June 21st-24th, 2000. Toronto, Canada. Poster Presentation No 2024 (2000).
   Google Scholar
• CHEN NY, CHEN WY, KOPCHICK JJ: A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology (1996) 137:5163–5165.
   PubMed Web of Science ®Google Scholar
• FLYBERG A, BENNETT WF, RASCH R, KOPCHICK JJ, SCARLET JA: Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin secretion in experimental diabetes in mice. Diabetes (1999) 48:377–382.
   PubMed Web of Science ®Google Scholar
• FLYVBJERG A, BENNETT WF, RASCHR, KOPCHICK JJ, SCARLETT JA:Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes (1999) 48:377–382.
   PubMed Web of Science ®Google Scholar
• HANKINSON SE, WILLETT WC, COLDITZ GA etal.: Circulating concentrations of insulin-like growth factor-land risk of breast cancer. Lancet (1998) 351:1393–1396.
   Google Scholar
• BRUNING PF, VAN DOORN J, BONFRER JM et al.: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int. J. Cancer (1995) 62:266-270, Published erratum appears in Int.J. Cancer (1995) 63(5):762.
   Google Scholar
• PEYRAT JP, BONNETERRE J, HECQUET B et al.: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J Cancer (1993) 29A:492–497.
   PubMed Web of Science ®Google Scholar
• BOHLKE K, CRAMER DW, TRICHOPOULOS D, MANTZOROS CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology (1998) 9:570–573.
   PubMed Web of Science ®Google Scholar
• WOLK A, MANTZOROS CS, ANDERSSON SO et al: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancerinst. (1998) 90:911–915.
   PubMed Web of Science ®Google Scholar
• ROSHAN SY, MCCUTCHEON IE, BENNETT WF et al: The growth hormone receptor antagonist B2036-PEG (Trovert) inhibits the growth of breast cancer xenografts in nude mice. Abstract. The Endocrine Society 81st Annual Meeting. June 12–15, 1999, San Diego California. Poster preserryation P2-122(1999).
   Google Scholar